Hepatitis C viral infection in patients with cirrhosis.
作者信息
Bahirwani Ranjeeta, Rajender Reddy K
机构信息
Division of Gastroenterology and Hepatology, Hospital of the University of Pennsylvania, Philadelphia, PA.
出版信息
Clin Liver Dis (Hoboken). 2012 Jul 23;1(3):65-68. doi: 10.1002/cld.43. eCollection 2012 Jul.
Abstract
摘要
相似文献
1
Hepatitis C viral infection in patients with cirrhosis.
Clin Liver Dis (Hoboken). 2012 Jul 23;1(3):65-68. doi: 10.1002/cld.43. eCollection 2012 Jul.
2
[Prevalence of hepatitis B and C viral infection according to the data on fetal outcomes in Moscow in 2015-2017].
Arkh Patol. 2019;81(2):29-35. doi: 10.17116/patol20198102129.
3
Predictive factors for development of cirrhosis in parenterally acquired chronic hepatitis C: a comparison between immunocompetent and immunocompromised patients.
J Hepatol. 1998 Jul;29(1):12-9. doi: 10.1016/s0168-8278(98)80173-6.
4
Cirrhosis of undefined pathogenesis: absence of evidence for unknown viruses or autoimmune processes.
Hepatology. 1993 Apr;17(4):593-8. doi: 10.1002/hep.1840170411.
5
Clinical significance of serum procalcitonin levels in patients with acute or chronic liver disease.
Eur J Gastroenterol Hepatol. 2006 May;18(5):525-30. doi: 10.1097/00042737-200605000-00012.
6
IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC.
J Hepatol. 2011 Apr;54(4):716-22. doi: 10.1016/j.jhep.2010.07.019. Epub 2010 Sep 19.
7
Quantifying the burden of chronic viral hepatitis-related cirrhosis hospitalizations in New Haven County, Connecticut.
Conn Med. 2008 Aug;72(7):393-7.
8
Epidemiology of hepatocellular carcinoma. Evaluation of viral and other risk factors in a low-endemic area for hepatitis B and C.
Z Gastroenterol. 1994 Mar;32(3):146-51.
9
Advances in Gut Microbiota of Viral Hepatitis Cirrhosis.
Biomed Res Int. 2019 Nov 22;2019:9726786. doi: 10.1155/2019/9726786. eCollection 2019.
10
Hepatitis viruses and liver transplantation.
J Gastroenterol Hepatol. 1997 Oct;12(9-10):S335-41. doi: 10.1111/j.1440-1746.1997.tb00518.x.
本文引用的文献
1
New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis.
Ann Intern Med. 2012 Feb 21;156(4):279-90. doi: 10.7326/0003-4819-156-4-201202210-00005.
2
Response-guided telaprevir combination treatment for hepatitis C virus infection.
N Engl J Med. 2011 Sep 15;365(11):1014-24. doi: 10.1056/NEJMoa1014463.
3
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases.
Hepatology. 2011 Oct;54(4):1433-44. doi: 10.1002/hep.24641. Epub 2011 Sep 26.
4
Telaprevir for retreatment of HCV infection.
N Engl J Med. 2011 Jun 23;364(25):2417-28. doi: 10.1056/NEJMoa1013086.
5
Telaprevir for previously untreated chronic hepatitis C virus infection.
N Engl J Med. 2011 Jun 23;364(25):2405-16. doi: 10.1056/NEJMoa1012912.
6
Boceprevir for previously treated chronic HCV genotype 1 infection.
N Engl J Med. 2011 Mar 31;364(13):1207-17. doi: 10.1056/NEJMoa1009482.
7
Boceprevir for untreated chronic HCV genotype 1 infection.
N Engl J Med. 2011 Mar 31;364(13):1195-206. doi: 10.1056/NEJMoa1010494.
8
Management of hepatocellular carcinoma: an update.
Hepatology. 2011 Mar;53(3):1020-2. doi: 10.1002/hep.24199.
9
A review of the treatment of chronic hepatitis C virus infection in cirrhosis.
Clin Ther. 2010 Dec;32(13):2117-38. doi: 10.1016/S0149-2918(11)00022-1.
10
Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
Liver Transpl. 2010 Jun;16(6):748-59. doi: 10.1002/lt.22072.
Zotero 插件